VistaGen Therapeutics
VTGN · Nasdaq · United States
Share price · VTGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VTGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Sep 2026+46.5%
- 30 Jun 2026-70.3%
- 26 Jun 2026+13.9%
Nothing announced by VTGN that day or the session before.
- 16 Jun 2026+20.4%
- 11 May 2026+10.3%
- 17 Dec 2025-80.3%
Nothing announced by VTGN that day or the session before.
- 11 Dec 2025-12.8%
Nothing announced by VTGN that day or the session before.
- 4 Dec 2025+14.7%
- 2 Dec 2025-18.7%
Nothing announced by VTGN that day or the session before.
Share of unusual movement by asset
For each asset, the share of VTGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Nasal chemosensory receptorsSmall molecule | Social Anxiety Disorder | |
AV-101No recent activity | Phase 2 | NMDA receptorSmall molecule | Major Depressive DisorderParkinson's Disease |
| Preclinical / Unstaged | —Small molecule | Major Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.1M | $6.5M | $11M+ $9.1M short-term inv. | $11M-$12M operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.5M | $11M | $17M+ $15M short-term inv. | $13M-$15M operating cash flow | report ↗ |
| 2025-Q4 | $0.3M | $14M | $47M+ $14M short-term inv. | $19M-$18M operating cash flow | report ↗ |
| 2025-Q3 | $0.3M | $16M | $63M+ $14M short-term inv. | $19M-$14M operating cash flow | report ↗ |
| 2025-Q2 | $0.2M | $12M | $49M+ $14M short-term inv. | $15M-$19M operating cash flow | report ↗ |
| 2024-Q4 | $0.2M | $11M | $75M+ $14M short-term inv. | $14M-$10M operating cash flow | report ↗ |
| 2024-Q3 | $0.2M | $10M | $84M+ $13M short-term inv. | $13M-$11M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $7.7M | $103M+ $5.5M short-term inv. | $11M-$11M operating cash flow | report ↗ |
| 2023-Q4 | $0.4M | $4.5M | $127M | $6.3M-$4.5M operating cash flow | report ↗ |
| 2023-Q3 | $0.3M | $3.9M | $38M | $6.6M-$6.2M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $4.2M | $9.6M | $6.9M-$7.9M operating cash flow | report ↗ |
| 2023-Q1 | — | $9.3M | $17M | $12M-$7.5M operating cash flow | report ↗ |
| 2022-Q4 | — | $6.8M | $25M | $9.8M-$9.9M operating cash flow | report ↗ |
| 2022-Q3 | — | $13M | $35M | $17M-$16M operating cash flow | report ↗ |
| 2022-Q2 | $0.3M | $15M | $52M | $20M-$16M operating cash flow | report ↗ |
| 2022-Q1 | — | $12M | $68M | $17M-$16M operating cash flow | report ↗ |
| 2021-Q4 | $0.4M | $8.0M | $84M | $11M-$12M operating cash flow | report ↗ |
| 2021-Q3 | $0.4M | $10M | $94M | $13M-$11M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $1.3M | $55M | $31M+ $15M short-term inv. | $17M-$66M operating cash flow | report ↗ |
VistaGen reported fiscal 2026 revenue of $1.27M, up 159.2% YoY, and R&D spend of $54.97M, up 39.6% YoY. Cash and equivalents were $30.79M, or $45.4M including marketable securities, and the company reported a net loss of $69.68M with a quarterly net burn of $69.69M.
The company completed the randomized portion of the PALISADE-4 Phase 3 trial of fasedienol for acute social anxiety disorder, with topline results expected in June 2026, and also completed the randomized portion of a fasedienol Phase 2 repeat-dose study, with topline results expected in the third quarter of 2026. Preliminary positive data were reported from the open-label extension of PALISADE-3, and the company said it had met minimum ICH E1 safety exposure recommendations across the fasedienol program. Refisolone received an FDA Study May Proceed letter under its IND for menopausal vasomotor symptoms, while itruvone preparation continued for major depressive disorder. Management also highlighted recent executive appointments and targeted cost-management initiatives, and stated that existing cash should fund operations into 2027.
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.5M | $39M | $67M+ $13M short-term inv. | $13M-$42M operating cash flow | report ↗ |
| 2024-FY | $1.1M | $20M | $119M+ $0 short-term inv. | $7.3M-$26M operating cash flow | report ↗ |
| 2023-FY | — | $44M | $17M | $15M-$50M operating cash flow | report ↗ |
| 2022-FY | $1.1M | $35M | $68M | $12M-$45M operating cash flow | report ↗ |
| 2021-FY | $1.1M | $12M | $103M | $4.5M-$12M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-29 | Williamson Douglas J · director | Award / grant (derivative) | 40,826 | — | — | Form 4 |
| 2026-06-30 | Singh Shawn · director, President and CEO | Award / grant | 36,818 | $0.19 | $7K | Form 4 |
| 2026-06-30 | Tressler Nick B. · Chief Financial Officer | Award / grant | 11,712 | $0.19 | $2K | Form 4 |
| 2026-06-30 | Adler Reid G. · Chief Legal Officer | Award / grant | 36,818 | $0.19 | $7K | Form 4 |
| 2026-05-18 | Angelov Angel S · Chief Medical Officer | Award / grant (derivative) | 150,000 | — | — | Form 4 |
| 2026-04-07 | Adler Reid G. · Chief Legal Officer | Award / grant (derivative) | 18,753 | — | — | Form 4 |
| 2026-04-07 | Cote Elissa S. · Chief Corp Development Officer | Award / grant (derivative) | 75,000 | — | — | Form 4 |
| 2026-04-07 | Prince Joshua S. · Chief Operating Officer | Award / grant (derivative) | 18,752 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 15.3M shares ($7.8M, 34.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 3,060,000 | $1.7M |
| 2 | TCG Crossover Management, LLC | 2,676,580 | $1.5M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1,574,200 | $900K |
| 4 | ADAR1 Capital Management, LLC | 751,141 | $429K |
| 5 | Ikarian Capital, LLC | 519,077 | $297K |
| 6 | TWO SIGMA INVESTMENTS, LP | 469,619 | $268K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 453,391 | $259K |
| 8 | BlackRock, Inc. | 448,507 | $256K |
| 9 | MILLENNIUM MANAGEMENT LLC | 430,404 | $246K |
| 10 | LUMINUS MANAGEMENT LLC | 396,053 | $226K |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 291,300 | $166K |
| 12 | AdvisorShares Investments LLC | 277,110 | $158K |
| 13 | JANE STREET GROUP, LLC | 272,811 | $156K |
| 14 | VANGUARD FIDUCIARY TRUST CO | 217,700 | $125K |
| 15 | STEMPOINT CAPITAL LP | 1,233,498 | $116K |